78 related articles for article (PubMed ID: 19148499)
1. Expression of heregulin, phosphorylated HER-2, HER-3 and HER-4 in HER-2 negative breast cancers.
Haas S; Gevensleben H; Rabstein S; Harth V; Pesch B; Brüning T; Justenhoven C; Brauch H; Hamann U; Ko YD; Baisch C; Fischer HP; Büttner R
Oncol Rep; 2009 Feb; 21(2):299-304. PubMed ID: 19148499
[TBL] [Abstract][Full Text] [Related]
2. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
Menendez JA; Mehmi I; Lupu R
J Clin Oncol; 2006 Aug; 24(23):3735-46. PubMed ID: 16847284
[TBL] [Abstract][Full Text] [Related]
3. Blocking HER-2/HER-3 function with a dominant negative form of HER-3 in cells stimulated by heregulin and in breast cancer cells with HER-2 gene amplification.
Ram TG; Schelling ME; Hosick HL
Cell Growth Differ; 2000 Mar; 11(3):173-83. PubMed ID: 10768865
[TBL] [Abstract][Full Text] [Related]
4. Herstatin inhibits heregulin-mediated breast cancer cell growth and overcomes tamoxifen resistance in breast cancer cells that overexpress HER-2.
Jhabvala-Romero F; Evans A; Guo S; Denton M; Clinton GM
Oncogene; 2003 Nov; 22(50):8178-86. PubMed ID: 14603258
[TBL] [Abstract][Full Text] [Related]
5. The outcome of heregulin-induced activation of ovarian cancer cells depends on the relative levels of HER-2 and HER-3 expression.
Xu F; Yu Y; Le XF; Boyer C; Mills GB; Bast RC
Clin Cancer Res; 1999 Nov; 5(11):3653-60. PubMed ID: 10589783
[TBL] [Abstract][Full Text] [Related]
6. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease.
Press MF; Pike MC; Chazin VR; Hung G; Udove JA; Markowicz M; Danyluk J; Godolphin W; Sliwkowski M; Akita R
Cancer Res; 1993 Oct; 53(20):4960-70. PubMed ID: 8104689
[TBL] [Abstract][Full Text] [Related]
7. Co-expression of ErbB-family members in human breast cancer: Her-2/neu is the preferred dimerization candidate in nodal-positive tumors.
Hudelist G; Singer CF; Manavi M; Pischinger K; Kubista E; Czerwenka K
Breast Cancer Res Treat; 2003 Aug; 80(3):353-61. PubMed ID: 14503808
[TBL] [Abstract][Full Text] [Related]
8. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
Lewis GD; Lofgren JA; McMurtrey AE; Nuijens A; Fendly BM; Bauer KD; Sliwkowski MX
Cancer Res; 1996 Mar; 56(6):1457-65. PubMed ID: 8640840
[TBL] [Abstract][Full Text] [Related]
9. Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
Arpino G; Weiss H; Lee AV; Schiff R; De Placido S; Osborne CK; Elledge RM
J Natl Cancer Inst; 2005 Sep; 97(17):1254-61. PubMed ID: 16145046
[TBL] [Abstract][Full Text] [Related]
10. Heregulin-triggered Her-2/neu signaling enhances nuclear accumulation of p21WAF1/CIP1 and protects breast cancer cells from cisplatin-induced genotoxic damage.
Menendez JA; Mehmi I; Lupu R
Int J Oncol; 2005 Mar; 26(3):649-59. PubMed ID: 15703820
[TBL] [Abstract][Full Text] [Related]
11. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
12. Phase II study of predictive biomarker profiles for response targeting human epidermal growth factor receptor 2 (HER-2) in advanced inflammatory breast cancer with lapatinib monotherapy.
Johnston S; Trudeau M; Kaufman B; Boussen H; Blackwell K; LoRusso P; Lombardi DP; Ben Ahmed S; Citrin DL; DeSilvio ML; Harris J; Westlund RE; Salazar V; Zaks TZ; Spector NL
J Clin Oncol; 2008 Mar; 26(7):1066-72. PubMed ID: 18212337
[TBL] [Abstract][Full Text] [Related]
13. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
[TBL] [Abstract][Full Text] [Related]
14. HER-2 gene amplification, HER-2 and epidermal growth factor receptor mRNA and protein expression, and lapatinib efficacy in women with metastatic breast cancer.
Press MF; Finn RS; Cameron D; Di Leo A; Geyer CE; Villalobos IE; Santiago A; Guzman R; Gasparyan A; Ma Y; Danenberg K; Martin AM; Williams L; Oliva C; Stein S; Gagnon R; Arbushites M; Koehler MT
Clin Cancer Res; 2008 Dec; 14(23):7861-70. PubMed ID: 19047115
[TBL] [Abstract][Full Text] [Related]
15. Expression of c-erbB receptors, heregulin and oestrogen receptor in human breast cell lines.
deFazio A; Chiew YE; Sini RL; Janes PW; Sutherland RL
Int J Cancer; 2000 Aug; 87(4):487-98. PubMed ID: 10918187
[TBL] [Abstract][Full Text] [Related]
16. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival.
Wiseman SM; Makretsov N; Nielsen TO; Gilks B; Yorida E; Cheang M; Turbin D; Gelmon K; Huntsman DG
Cancer; 2005 May; 103(9):1770-7. PubMed ID: 15770691
[TBL] [Abstract][Full Text] [Related]
17. Heregulin selectively upregulates vascular endothelial growth factor secretion in cancer cells and stimulates angiogenesis.
Yen L; You XL; Al Moustafa AE; Batist G; Hynes NE; Mader S; Meloche S; Alaoui-Jamali MA
Oncogene; 2000 Jul; 19(31):3460-9. PubMed ID: 10918604
[TBL] [Abstract][Full Text] [Related]
18. Proteomics of breast cancer: enhanced expression of cytokeratin19 in human epidermal growth factor receptor type 2 positive breast tumors.
Zhang DH; Tai LK; Wong LL; Sethi SK; Koay ES
Proteomics; 2005 May; 5(7):1797-805. PubMed ID: 15825149
[TBL] [Abstract][Full Text] [Related]
19. Amplified in breast cancer 1 in human epidermal growth factor receptor - positive tumors of tamoxifen-treated breast cancer patients.
Kirkegaard T; McGlynn LM; Campbell FM; Müller S; Tovey SM; Dunne B; Nielsen KV; Cooke TG; Bartlett JM
Clin Cancer Res; 2007 Mar; 13(5):1405-11. PubMed ID: 17332282
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up.
Rydén L; Jirström K; Haglund M; Stål O; Fernö M
Breast Cancer Res Treat; 2010 Apr; 120(2):491-8. PubMed ID: 20135347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
